成人社區獲得性肺炎初始治療失敗診治進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

李秀梅 ¹ ^# , 韓秀迪 ¹ ^# , 劉德順 ² ,  劉學東 ²

1. ;
2. ;

Corresponding?author：

劉學東, Email: xuedongliu@263.net

Keywords：

DOI：

10.7507/1671-6205.201809057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李秀梅, 韓秀迪, 劉德順, 劉學東. 成人社區獲得性肺炎初始治療失敗診治進展. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(5): 499-504. doi: 10.7507/1671-6205.201809057 Copy

1.	Ott SR, Hauptmeier BM, Ernen C, et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J, 2012, 39(3): 611-618.
2.	Oster G, Berger A, Edelsberg J, et al. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ, 2013, 16(6): 809-819.
3.	Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis, 2007, 44(Suppl 2): S27-S72.
4.	中華醫學會呼吸病學分會. 中國成人社區獲得性肺炎診斷和治療指南 (2016 年版). 中華結核和呼吸雜志, 2016, 39(4): 253-279.
5.	李郁, 劉磊. 難治性肺炎的治療體會. 中國醫院用藥評價與分析, 2014, 14(2): 177-179.
6.	Rosón B, Carratalà J, Fernández-Sabé N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med, 2004, 164(5): 502-508.
7.	Menéndez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J, 2012, 39(1): 156-162.
8.	梅靜, 楊進, 蔣建軍, 等. 三種評分系統對重癥社區獲得性肺炎患者嚴重程度的預測價值. 臨床肺科雜志, 2018, 23(6): 1038-1042.
9.	Sialer S, Liapikou A, Torres A. What is the best approach to the nonresponding patient with community-acquired pneumonia?. Infect Dis Clin North Am, 2013, 27(1): 189-203.
10.	Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest, 2008, 134(5): 955-962.
11.	Sharma L, Losier A, Tolbert T, et al. Atypical pneumonia: updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clin Chest Med, 2017, 38(1): 45-58.
12.	Cillóniz C, Gabarrús A, Ferrer M, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa. Chest, 2016, 150(2): 415-425.
13.	Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis, 2012, 54(8): 1126-1133.
14.	中華醫學會呼吸病學分會感染學組. 肺真菌病診斷和治療專家共識. 中華結核和呼吸雜志, 2007, 30(11): 821-834.
15.	郭穎, 何花貞, 孫征. 肺結核合并肺部真菌感染的臨床特點及危險因素. 中國老年學雜志, 2019, 39(2): 294-297.
16.	鄧紫薇, 仇成鳳, 李茂作, 等. 成人社區獲得性肺炎主要病原體分布的 Meta 分析. 中國抗生素雜志, 2016, 41(12): 950-955.
17.	張英, 韓俊, 但漢雄. 老年社區獲得性肺炎相關高危因素分析研究. 臨床肺科雜志, 2018, 23(3): 470-472.
18.	Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J, 2008, 32(1): 139-146.
19.	陳曉斐, 徐志豪, 董大鵬. CXCR1、CXCR2 及 IL-8 在老年社區獲得性肺炎患者病情及預后評估中的作用. 中國老年學雜志, 2018, 38(9): 2120-2121.
20.	邱虹, 王衛彪, 李岱, 等. 老年社區獲得性肺炎患者的病原菌種類及其耐藥情況分析. 中華老年醫學雜志, 2018, 37(12): 1365-1368.
21.	Welte T. Managing CAP patients at risk of clinical failure. Respir Med, 2015, 109(2): 157-169.
22.	Sousa D, Justo I, Domínguez A, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect, 2013, 19(2): 187-192.
23.	Ernst P, Suissa S. Inhaled corticosteroids and mortality in COPD. Chest, 2006, 130(3): 640-646.
24.	Bansal V, Mangi MA, Johnson MM, et al. Inhaled corticosteroids and incident pneumonia in patients with asthma: systematic review and meta-analysis. Acta Med Acad, 2015, 44(2): 135-158.
25.	Joo MJ, Au DH, Fitzgibbon ML, et al. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med, 2010, 104(2): 246-252.
26.	Jiang HL, Chen HX, Liu W, et al. Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis. Respirology, 2015, 20(7): 1046-1054.
27.	李麗娟, 劉穎梅, 王一民, 等. 糖皮質激素長期應用宿主合并社區獲得性肺炎的臨床特征及預后分析. 中華醫學雜志, 2018, 98(10): 738-743.
28.	Iqbal N, Irfan M, Zubairi A, et al. Association of hypercapnia on admission with increased length of hospital stay and severity in patients admitted with community-acquired pneumonia: a prospective observational study from Pakistan. BMJ Open, 2017, 7(6): e013924.
29.	Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax, 2009, 64(7): 587-591.
30.	Falguera M, Carratalà J, Bielsa S, et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J, 2011, 38(5): 1173-1179.
31.	Dean NC, Griffith PP, Sorensen JS, et al. Pleural effusions at first ED encounter predict worse clinical outcomes in patients with pneumonia. Chest, 2016, 149(6): 1509-1515.
32.	南凱, 郝利鋒, 劉斯文, 等. 社區獲得性肺炎患者早期治療失敗的相關因素分析. 河北醫藥, 2017, 39(24): 3730-3732, 3736.
33.	Washio Y, Ito A, Kumagai S, et al. A model for predicting bacteremia in patients with community-acquired pneumococcal pneumonia: a retrospective observational study. BMC Pulm Med, 2018, 18(1): 24.
34.	Akyil FT, Yalcinsoy M, Hazar A, et al. Prognosis of hospitalized patients with community-acquired pneumonia. Rev Port Pneumol (2006), 2018: S2173511517301562.
35.	Han X, Zhou F, Li H, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis, 2018, 18(1): 192.
36.	Genné D, Sommer R, Kaiser L, et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis, 2006, 25(3): 159-166.
37.	Nie XM, Li YS, Yang ZW, et al. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clin Microbiol Infect, 2018, 24(6): 658.e1-658.e6.
38.	發熱伴肺部陰影鑒別診斷共識專家組. 發熱伴肺部陰影鑒別診斷專家共識. 中華結核和呼吸雜志, 2016, 39(3): 169-176.
39.	李輝, 曹彬. 肺炎鏈球菌尿抗原檢測方法在社區獲得性肺炎診治中的應用價值. 中華結核和呼吸雜志, 2015, 38(1): 66-69.
40.	彭春紅, 葉賢偉, 張湘燕. 社區獲得性肺炎病原譜的構成及病原菌快速檢測方法的進展. 中華結核和呼吸雜志, 2016, 39(4): 311-312.
41.	Rubin R. Why are Legionnaires disease diagnoses becoming more common in the United States?. JAMA, 2018, 319(17): 1753-1754.
42.	金麗媛, 陳愉, 劉宏博, 等. 初始治療失敗重癥軍團菌肺炎一例. 中華醫學雜志, 2018, 98(48): 3983-3984.
43.	劉利華, 張玉芹, 董海新, 等. 痰真菌培養聯合半乳甘露聚糖試驗對侵襲性肺曲霉病的診斷價值. 中國中西醫結合急救雜志, 2018, 25(2): 189-193.
44.	曹彬. 關注成人社區獲得性肺炎中病毒性肺炎的診治. 中華結核和呼吸雜志, 2016, 39(7): 569-570.
45.	Leprince C, Desroches M, Emirian A, et al. Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study. Diagn Microbiol Infect Dis, 2015, 83(2): 175-182.
46.	Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med, 2015, 372(14): 1312-1323.
47.	張能華. 降鈣素原、超敏 C-反應蛋白和白細胞計數在肺炎患者中的臨床應用價值. 中國衛生檢驗雜志, 2016, 26(19): 2796-2798.
48.	Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax, 2008, 63(5): 447-452.
49.	Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis, 2011, 52(Suppl 4): S346-S350.
50.	Schuetz P, Wirz Y, Mueller B. Procalcitonin testing to guide antibiotic therapy in acute upper and lower respiratory tract infections. JAMA, 2018, 319(9): 925-926.
51.	郭亞威, 王萌, 朱丹丹, 等. 降鈣素原聯合 CURB-65 評分對老年社區獲得性肺炎患者預后的評估價值. 中國綜合臨床, 2019, 35(1): 73-76.
52.	Self WH, Grijalva CG, Williams DJ, et al. Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with community-acquired pneumonia. Chest, 2016, 150(4): 819-828.
53.	中國醫藥教育協會感染疾病專業委員會. 感染相關生物標志物臨床意義解讀專家共識. 中華結核和呼吸雜志, 2017, 40(4): 243-257.
54.	Martin-Loeches I, Valles X, Menendez R, et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res, 2014, 15(1): 75.
55.	李京, 楊建坤, 趙麗, 等. B 型鈉尿肽對社區獲得性肺炎危險分層的價值. 臨床和實驗醫學雜志, 2019, 18(2): 168-171.
56.	張潔, 解立新, 謝良地. D-二聚體對社區獲得性肺炎患者病情嚴重程度及預后的評估價值. 中華危重病急救醫學, 2016, 28(9): 769-774.
57.	張靜, 劉冬, 許西琳, 等. 紅細胞分布寬度與成人社區獲得性肺炎嚴重程度的相關性分析. 中國呼吸與危重監護雜志, 2018, 17(2): 134-137.
58.	Wang Y, Guo Q, Yan Z, et al. Factors associated with prolonged viral shedding in patients with avian influenza A (H7N9) virus infection. J Infect Dis, 2018, 217(11): 417-429.
59.	?illi A. Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia. Tuberk Toraks, 2015, 63(2): 94-101.
60.	Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis, 2009, 200(4): 492-500.
61.	Cao B, Gao HN, Zhou BP, et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med, 2016, 44(6): e318-e328.
62.	Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin Ⅱ receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis, 2012, 55(11): 1466-1473.
63.	Troeman DPR, Postma DF, van Werkhoven CH, et al. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect, 2013, 67(2): 93-101.
64.	汪劭婷, 孫雪峰. 他汀類藥物對社區獲得性肺炎治療作用及患病風險的 Meta 分析. 中國醫學科學院學報, 2018, 40(1): 30-40.
65.	范志強, 瞿介明, 朱惠莉. 吸入性肺炎的研究進展. 中國呼吸與危重監護雜志, 2010, 9(2): 209-212.

1. Ott SR, Hauptmeier BM, Ernen C, et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J, 2012, 39(3): 611-618.
2. Oster G, Berger A, Edelsberg J, et al. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ, 2013, 16(6): 809-819.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis, 2007, 44(Suppl 2): S27-S72.
4. 中華醫學會呼吸病學分會. 中國成人社區獲得性肺炎診斷和治療指南 (2016 年版). 中華結核和呼吸雜志, 2016, 39(4): 253-279.
5. 李郁, 劉磊. 難治性肺炎的治療體會. 中國醫院用藥評價與分析, 2014, 14(2): 177-179.
6. Rosón B, Carratalà J, Fernández-Sabé N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med, 2004, 164(5): 502-508.
7. Menéndez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J, 2012, 39(1): 156-162.
8. 梅靜, 楊進, 蔣建軍, 等. 三種評分系統對重癥社區獲得性肺炎患者嚴重程度的預測價值. 臨床肺科雜志, 2018, 23(6): 1038-1042.
9. Sialer S, Liapikou A, Torres A. What is the best approach to the nonresponding patient with community-acquired pneumonia?. Infect Dis Clin North Am, 2013, 27(1): 189-203.
10. Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest, 2008, 134(5): 955-962.
11. Sharma L, Losier A, Tolbert T, et al. Atypical pneumonia: updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clin Chest Med, 2017, 38(1): 45-58.
12. Cillóniz C, Gabarrús A, Ferrer M, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa. Chest, 2016, 150(2): 415-425.
13. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis, 2012, 54(8): 1126-1133.
14. 中華醫學會呼吸病學分會感染學組. 肺真菌病診斷和治療專家共識. 中華結核和呼吸雜志, 2007, 30(11): 821-834.
15. 郭穎, 何花貞, 孫征. 肺結核合并肺部真菌感染的臨床特點及危險因素. 中國老年學雜志, 2019, 39(2): 294-297.
16. 鄧紫薇, 仇成鳳, 李茂作, 等. 成人社區獲得性肺炎主要病原體分布的 Meta 分析. 中國抗生素雜志, 2016, 41(12): 950-955.
17. 張英, 韓俊, 但漢雄. 老年社區獲得性肺炎相關高危因素分析研究. 臨床肺科雜志, 2018, 23(3): 470-472.
18. Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J, 2008, 32(1): 139-146.
19. 陳曉斐, 徐志豪, 董大鵬. CXCR1、CXCR2 及 IL-8 在老年社區獲得性肺炎患者病情及預后評估中的作用. 中國老年學雜志, 2018, 38(9): 2120-2121.
20. 邱虹, 王衛彪, 李岱, 等. 老年社區獲得性肺炎患者的病原菌種類及其耐藥情況分析. 中華老年醫學雜志, 2018, 37(12): 1365-1368.
21. Welte T. Managing CAP patients at risk of clinical failure. Respir Med, 2015, 109(2): 157-169.
22. Sousa D, Justo I, Domínguez A, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect, 2013, 19(2): 187-192.
23. Ernst P, Suissa S. Inhaled corticosteroids and mortality in COPD. Chest, 2006, 130(3): 640-646.
24. Bansal V, Mangi MA, Johnson MM, et al. Inhaled corticosteroids and incident pneumonia in patients with asthma: systematic review and meta-analysis. Acta Med Acad, 2015, 44(2): 135-158.
25. Joo MJ, Au DH, Fitzgibbon ML, et al. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med, 2010, 104(2): 246-252.
26. Jiang HL, Chen HX, Liu W, et al. Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis. Respirology, 2015, 20(7): 1046-1054.
27. 李麗娟, 劉穎梅, 王一民, 等. 糖皮質激素長期應用宿主合并社區獲得性肺炎的臨床特征及預后分析. 中華醫學雜志, 2018, 98(10): 738-743.
28. Iqbal N, Irfan M, Zubairi A, et al. Association of hypercapnia on admission with increased length of hospital stay and severity in patients admitted with community-acquired pneumonia: a prospective observational study from Pakistan. BMJ Open, 2017, 7(6): e013924.
29. Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax, 2009, 64(7): 587-591.
30. Falguera M, Carratalà J, Bielsa S, et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J, 2011, 38(5): 1173-1179.
31. Dean NC, Griffith PP, Sorensen JS, et al. Pleural effusions at first ED encounter predict worse clinical outcomes in patients with pneumonia. Chest, 2016, 149(6): 1509-1515.
32. 南凱, 郝利鋒, 劉斯文, 等. 社區獲得性肺炎患者早期治療失敗的相關因素分析. 河北醫藥, 2017, 39(24): 3730-3732, 3736.
33. Washio Y, Ito A, Kumagai S, et al. A model for predicting bacteremia in patients with community-acquired pneumococcal pneumonia: a retrospective observational study. BMC Pulm Med, 2018, 18(1): 24.
34. Akyil FT, Yalcinsoy M, Hazar A, et al. Prognosis of hospitalized patients with community-acquired pneumonia. Rev Port Pneumol (2006), 2018: S2173511517301562.
35. Han X, Zhou F, Li H, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis, 2018, 18(1): 192.
36. Genné D, Sommer R, Kaiser L, et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis, 2006, 25(3): 159-166.
37. Nie XM, Li YS, Yang ZW, et al. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clin Microbiol Infect, 2018, 24(6): 658.e1-658.e6.
38. 發熱伴肺部陰影鑒別診斷共識專家組. 發熱伴肺部陰影鑒別診斷專家共識. 中華結核和呼吸雜志, 2016, 39(3): 169-176.
39. 李輝, 曹彬. 肺炎鏈球菌尿抗原檢測方法在社區獲得性肺炎診治中的應用價值. 中華結核和呼吸雜志, 2015, 38(1): 66-69.
40. 彭春紅, 葉賢偉, 張湘燕. 社區獲得性肺炎病原譜的構成及病原菌快速檢測方法的進展. 中華結核和呼吸雜志, 2016, 39(4): 311-312.
41. Rubin R. Why are Legionnaires disease diagnoses becoming more common in the United States?. JAMA, 2018, 319(17): 1753-1754.
42. 金麗媛, 陳愉, 劉宏博, 等. 初始治療失敗重癥軍團菌肺炎一例. 中華醫學雜志, 2018, 98(48): 3983-3984.
43. 劉利華, 張玉芹, 董海新, 等. 痰真菌培養聯合半乳甘露聚糖試驗對侵襲性肺曲霉病的診斷價值. 中國中西醫結合急救雜志, 2018, 25(2): 189-193.
44. 曹彬. 關注成人社區獲得性肺炎中病毒性肺炎的診治. 中華結核和呼吸雜志, 2016, 39(7): 569-570.
45. Leprince C, Desroches M, Emirian A, et al. Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study. Diagn Microbiol Infect Dis, 2015, 83(2): 175-182.
46. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med, 2015, 372(14): 1312-1323.
47. 張能華. 降鈣素原、超敏 C-反應蛋白和白細胞計數在肺炎患者中的臨床應用價值. 中國衛生檢驗雜志, 2016, 26(19): 2796-2798.
48. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax, 2008, 63(5): 447-452.
49. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis, 2011, 52(Suppl 4): S346-S350.
50. Schuetz P, Wirz Y, Mueller B. Procalcitonin testing to guide antibiotic therapy in acute upper and lower respiratory tract infections. JAMA, 2018, 319(9): 925-926.
51. 郭亞威, 王萌, 朱丹丹, 等. 降鈣素原聯合 CURB-65 評分對老年社區獲得性肺炎患者預后的評估價值. 中國綜合臨床, 2019, 35(1): 73-76.
52. Self WH, Grijalva CG, Williams DJ, et al. Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with community-acquired pneumonia. Chest, 2016, 150(4): 819-828.
53. 中國醫藥教育協會感染疾病專業委員會. 感染相關生物標志物臨床意義解讀專家共識. 中華結核和呼吸雜志, 2017, 40(4): 243-257.
54. Martin-Loeches I, Valles X, Menendez R, et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res, 2014, 15(1): 75.
55. 李京, 楊建坤, 趙麗, 等. B 型鈉尿肽對社區獲得性肺炎危險分層的價值. 臨床和實驗醫學雜志, 2019, 18(2): 168-171.
56. 張潔, 解立新, 謝良地. D-二聚體對社區獲得性肺炎患者病情嚴重程度及預后的評估價值. 中華危重病急救醫學, 2016, 28(9): 769-774.
57. 張靜, 劉冬, 許西琳, 等. 紅細胞分布寬度與成人社區獲得性肺炎嚴重程度的相關性分析. 中國呼吸與危重監護雜志, 2018, 17(2): 134-137.
58. Wang Y, Guo Q, Yan Z, et al. Factors associated with prolonged viral shedding in patients with avian influenza A (H7N9) virus infection. J Infect Dis, 2018, 217(11): 417-429.
59. ?illi A. Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia. Tuberk Toraks, 2015, 63(2): 94-101.
60. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis, 2009, 200(4): 492-500.
61. Cao B, Gao HN, Zhou BP, et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med, 2016, 44(6): e318-e328.
62. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin Ⅱ receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis, 2012, 55(11): 1466-1473.
63. Troeman DPR, Postma DF, van Werkhoven CH, et al. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect, 2013, 67(2): 93-101.
64. 汪劭婷, 孫雪峰. 他汀類藥物對社區獲得性肺炎治療作用及患病風險的 Meta 分析. 中國醫學科學院學報, 2018, 40(1): 30-40.
65. 范志強, 瞿介明, 朱惠莉. 吸入性肺炎的研究進展. 中國呼吸與危重監護雜志, 2010, 9(2): 209-212.

Previous Article
青蒿琥酯對哮喘治療作用的研究進展
Next Article
支氣管內超聲實時彈性成像技術的應用及研究進展

Chinese Journal of Respiratory and Critical Care Medicine

成人社區獲得性肺炎初始治療失敗診治進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content